Q1 Earnings Estimate for ALDX Issued By Leerink Partnrs

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Aldeyra Therapeutics in a research note issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman forecasts that the biotechnology company will post earnings per share of ($0.27) for the quarter. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.92) per share. Leerink Partnrs also issued estimates for Aldeyra Therapeutics’ Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($1.00) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($0.45) EPS and FY2028 earnings at $0.75 EPS.

A number of other equities analysts also recently issued reports on the company. BTIG Research decreased their price objective on Aldeyra Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Monday, April 7th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, April 4th.

Aldeyra Therapeutics Stock Up 9.0 %

Shares of NASDAQ ALDX opened at $2.19 on Wednesday. The firm has a fifty day simple moving average of $5.23 and a two-hundred day simple moving average of $5.17. Aldeyra Therapeutics has a 12 month low of $1.14 and a 12 month high of $7.20. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $130.76 million, a PE ratio of -2.33 and a beta of 0.94.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its quarterly earnings data on Thursday, March 6th. The biotechnology company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.30).

Insider Transactions at Aldeyra Therapeutics

In related news, major shareholder Perceptive Advisors Llc sold 3,400,000 shares of the business’s stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $1.42, for a total value of $4,828,000.00. Following the transaction, the insider now directly owns 5,875,851 shares of the company’s stock, valued at approximately $8,343,708.42. The trade was a 36.65 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 8.50% of the company’s stock.

Institutional Trading of Aldeyra Therapeutics

A number of large investors have recently made changes to their positions in the business. Raymond James Financial Inc. purchased a new stake in shares of Aldeyra Therapeutics in the fourth quarter valued at $3,628,000. State Street Corp grew its holdings in Aldeyra Therapeutics by 1.7% during the 3rd quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock valued at $5,249,000 after purchasing an additional 16,188 shares during the last quarter. Barclays PLC grew its holdings in Aldeyra Therapeutics by 280.1% during the 3rd quarter. Barclays PLC now owns 65,561 shares of the biotechnology company’s stock valued at $353,000 after purchasing an additional 48,313 shares during the last quarter. SG Americas Securities LLC lifted its stake in Aldeyra Therapeutics by 14.4% in the fourth quarter. SG Americas Securities LLC now owns 22,365 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 2,822 shares during the last quarter. Finally, AlphaCentric Advisors LLC purchased a new position in shares of Aldeyra Therapeutics during the fourth quarter valued at approximately $234,000. 59.71% of the stock is currently owned by institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.